United Services Automobile Association decreased its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 39.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 10,418 shares of the life sciences company's stock after selling 6,748 shares during the period. United Services Automobile Association's holdings in Illumina were worth $1,359,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the business. Cetera Investment Advisers raised its stake in Illumina by 361.1% during the first quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company's stock worth $2,007,000 after acquiring an additional 11,447 shares in the last quarter. Cetera Advisors LLC bought a new position in Illumina in the 1st quarter valued at approximately $610,000. Securian Asset Management Inc. boosted its position in Illumina by 36.3% in the second quarter. Securian Asset Management Inc. now owns 12,705 shares of the life sciences company's stock valued at $1,326,000 after buying an additional 3,384 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Illumina by 23.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,755 shares of the life sciences company's stock valued at $1,018,000 after buying an additional 1,831 shares in the last quarter. Finally, Great Valley Advisor Group Inc. bought a new stake in shares of Illumina during the second quarter worth $201,000. Institutional investors and hedge funds own 89.42% of the company's stock.
Illumina Stock Up 0.8 %
Shares of Illumina stock traded up $1.18 during trading on Friday, reaching $141.09. 1,106,683 shares of the company traded hands, compared to its average volume of 2,073,166. The firm has a market capitalization of $22.38 billion, a PE ratio of -14.17 and a beta of 1.11. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a 50 day moving average price of $143.12 and a 200-day moving average price of $127.16. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.08 billion. During the same quarter in the prior year, the firm earned $0.33 EPS. The business's revenue was down 3.5% on a year-over-year basis. As a group, equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
ILMN has been the topic of several recent research reports. Daiwa America raised Illumina to a "strong-buy" rating in a report on Friday, August 16th. Argus raised Illumina from a "hold" rating to a "buy" rating and set a $150.00 price target on the stock in a research note on Wednesday, August 28th. Daiwa Capital Markets raised Illumina from a "neutral" rating to a "buy" rating and upped their price objective for the company from $120.00 to $154.00 in a research note on Friday, August 16th. Leerink Partners raised their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus target price of $164.00.
Get Our Latest Stock Report on ILMN
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
